In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...